Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia.
10.7534/j.issn.1009-2137.2014.03.057
- Author:
Chen ZHU
1
;
Yan MA
1
;
Xiao-Ping XU
2
Author Information
1. Department of Hematology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China.
2. Department of Hematology, Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China. E-mail: xpxu1111@163.com.
- Publication Type:Journal Article
- MeSH:
DNA (Cytosine-5-)-Methyltransferases;
genetics;
DNA-Binding Proteins;
genetics;
Genotype;
Humans;
Isocitrate Dehydrogenase;
genetics;
Leukemia, Myeloid, Acute;
genetics;
pathology;
Myelodysplastic Syndromes;
genetics;
pathology;
Nuclear Proteins;
genetics;
Oncogenes;
Proto-Oncogene Proteins;
genetics;
Repressor Proteins;
genetics;
Ribonucleoproteins;
genetics;
Serine-Arginine Splicing Factors
- From:
Journal of Experimental Hematology
2014;22(3):873-878
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome (MDS) is highly heterogeneous clonal hematological malignancy, having a high rate of progression to acute myeloid leukemia (AML). With the rapid development of molecular biological techniques, plenty of gene mutations were found to have close relationships with the transformation from MDS to AML. SRSF2 is a RNA splicing-related gene, which mutation may prompt a poor prognosis, and have a higher rate of progressing to AML. DNMT3A plays an important role in DNA methylation, its mutation often indicate a worse overall survival and a more rapid progression to AML. ASXL1 regulates the synthesis of histone, which frameshift mutations are molecular marks of an adverse outcome. IDH contains IDH1 and IDH2, which are related with the Krebs cycle. Patients with IDH1 mutation have a shorter overall survival and a higher risk of AML transformation than that of patients with wild-type IDH1, while IDH2 was a poor prognostic factor for overall survival in patients with lower-risk MDS. Another gene related with DNA methylation is TET2, which is the most frequently mutated gene in MDS known so far and it may act as tumor-suppressor gene, but the opinions on its impact on patients' outcomes are still controversial. Some studies show that its mutations relate to a shorter time to progression to AML. Because of the differentiations in patients' races, regions and clinical characteristics, the results of different studies are varied. In this review, the recent advances on these related genes are summarized.
